<DOC>
	<DOCNO>NCT01130623</DOCNO>
	<brief_summary>Background : - Pazopanib , drug inhibits growth new blood vessel tumor , recently approve Food Drug Administration treat advance kidney cancer adult . Pazopanib use small number adult , research need whether safe effective use child . Researchers interested determine safe effective treatment dos pazopanib child , study examine form pazopanib treatment ( tablet liquid ) effective well tolerate . Objectives : - To determine safe effective dose pazopanib treat solid tumor child . - To study effect pazopanib blood cell , blood flow , human development . Eligibility : - Children , adolescent , young adult 1 21 year age diagnose solid tumor respond treatment . Design : - Eligible participant screen physical examination , blood tumor sample , image study . - Participants receive pazopanib tablet 28-day cycle treatment . Pazopanib take empty stomach , least 1hour 2 hour meal . Participants may receive pazopanib 24 cycle unless tumor respond participant develop serious side effect . - Blood sample take day 1 , 15 , 22 , 27 first cycle pazopanib , additional sample take every 8 week subsequent cycle . - An optional part study collect additional blood sample regular interval 24 hour first dose pazopanib regular interval another dose second third week first treatment cycle .</brief_summary>
	<brief_title>A Phase I Study Pazopanib Single Agent Children With Refractory Solid Tumors</brief_title>
	<detailed_description>Background : - Pazopanib potent selective multi-target receptor tyrosine kinase inhibitor vascular endothelial growth factor ( VEGF ) receptor ( VEGFR ) -1 , -2 , -3 , c-kit platelet derive growth factor ( PDGF ) receptors-alpha -beta . - Preclinical experiment demonstrate pazopanib cause significant dose-dependent inhibitory effect cell proliferation inhibition VEGF-induced VEGFR-2 phosphorylation , growth inhibition variety human tumor xenograft mouse , inhibition basic fibroblast growth factor- ( bFGF ) VEGF-induced angiogenesis murine model . - Pazopanib evaluate adult subject solid tumor Phase I II study , objective anti-tumor activity observe variety tumor type . Objectives : Primary Objectives : - To estimate maximum tolerate dose ( MTD ) and/or recommend Phase II dose oral pazopanib administer daily schedule child refractory solid tumor . - To define toxicity oral pazopanib administer either tablet suspension . - To characterize pharmacokinetics oral pazopanib child refractory solid tumor . Secondary Objectives : - To preliminarily define antitumor biologic activity oral pazopanib , explore change tumor vascular permeability follow initiation pazopanib . - To preliminarily assess VEGF haplotype/phenotype relationship child cancer . - To explore pazopanib concentration-effect relationship biomarkers clinical outcome . Eligibility : - Part 1 ( Phase I Dose Escalation ) 2a ( Suspension Formulation Component ) : -- Patients great 12 month less equal 21 year age measureable evaluable relapse refractory solid tumor include CNS tumor histologic verification except patient intrinsic brain stem tumor , optic pathway glioma , patient pineal tumor elevation tumor marker . - Part 2b ( Expanded Imaging Cohort ) : -- Patients great 2 year less equal 25 year age histologically verify relapsed refractory soft tissue sarcoma , desmoplastic small round cell tumor extraosseus Ewing sarcoma measurable disease ( great equal 2 cm ) head , neck , extremity fix within thorax , abdomen pelvis . - Performance score : Karnofsky great equal 50 % patient 16 year age ; Lansky great equal 50 patient less equal 16 year age . - Must fully recover acute toxic effect prior therapy complete within specify prior time frame . Have adequate organ function determine laboratory evaluation . Design : - This roll six phase I trial design pazopanib administer orally daily continuously 28 day cycle . - Therapy may continue 24 cycle absence progressive disease unacceptable toxicity . - Part 1 phase I dose escalation portion ( Completed ) . Once MTD phase II recommend dose define , 16 additional patient enroll Part 2a obtain safety pharmacokinetic data suspension formulation . In addition , 10 patient recurrent/refractory soft tissue sarcoma measurable lesion enrol Part 2b MTD recommend Phase II dose explore change tumor vascular permeability use dynamic contrast enhance MRI . - Participation correlative biology study pharmacokinetic study optional Part 1 ; pharmacokinetic study require Part 2a ; image limited pharmacokinetic sampling require Part 2b .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<criteria>Eligibility : Part 1 ( Phase I Dose Escalation ) 2a ( Suspension Formulation Component ) : Patients great 12 month less equal 21 year age measureable evaluable relapse refractory solid tumor include CNS tumor histologic verification except patient intrinsic brain stem tumor , optic pathway glioma , patient pineal tumor elevation tumor marker . Part 2b ( Expanded Imaging Cohort ) : Patients great 2 year less equal 25 year age histologically verify relapsed refractory soft tissue sarcoma , desmoplastic small round cell tumor extraosseus Ewing sarcoma measurable disease ( great equal 2 cm ) head , neck , extremity fix within thorax , abdomen pelvis . Performance score : Karnofsky great equal 50 % patient 16 year age ; Lansky great equal 50 patient less equal 16 year age . Must fully recover acute toxic effect prior therapy complete within specify prior time frame . Have adequate organ function determine laboratory evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 18, 2011</verification_date>
	<keyword>VEGF Inhibitor</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Antitumor Activity</keyword>
	<keyword>Pediatric Cancer</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Wilms Tumor</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>